MVT 102
Alternative Names: MVT-102Latest Information Update: 28 Mar 2024
At a glance
- Originator Microvascular Therapeutics
- Class Contrast media; Diagnostic agents; Imaging agents
- Mechanism of Action Diagnostic imaging enhancers; Ultrasonography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease(Diagnosis) in USA (Parenteral)
- 15 Jul 2022 Microvascular Therapeutics has filed provisional patent application for MVT 102 in the US (Microvascular Therapeutics pipeline, July 2022)
- 06 Feb 2020 Preclinical trials in Alzheimer's disease in USA (Parenteral) (Microvascular therapeutics pipeline February 2020)